Prothena Corporation plc
corporate_fare Company Profile
Prothena Corporation plc (NASDAQ:PRTA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 12 items for PRTA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-08-06, rated 7/10. Across its 12 most recent items scored 7 or higher, the top rating is 9/10, with 6 rated 8 or above. Recent SEC coverage for PRTA spans 10-Q, 144, 8-K, DEF 14A.
Recent high-impact activity:
- Prothena Q2 2026: Net Loss Narrows to $18.6M as Restructuring Winds Down; Cash at $288M
- Prothena Posts Q2 Results, Highlights $3B in Potential Milestones from Partnered Pipeline
- Previous Officer Files Intent to Sell $740K in Stock
- Prothena Swings to Profit in Q1 with $51M Revenue, Driven by Novo Nordisk Milestone
- Prothena Reports Strong Q1 Net Income Driven by $50M Coramitug Milestone, Advances Key Clinical Programs
Financial Snapshot
Short Interest & Short Volume
26.53 days to coverFINRA reported short interest of 8,544,664 shares in PRTA as of the September 15, 2026 settlement, a 0.6% increase from the prior period — about 26.5 days to cover at its recent average daily volume. On October 2, 2026, 71.1% of PRTA volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.